Holen Sie sich die Stockscreener-App
35.18
0.76%
-0.27
Handel nachbörslich:
35.40
0.22
+0.63%
Schlusskurs vom Vortag:
$35.45
Offen:
$35.94
24-Stunden-Volumen:
1.11M
Relative Volume:
0.71
Marktkapitalisierung:
$2.53B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-368.95M
KGV:
-6.3441
EPS:
-5.5453
Netto-Cashflow:
$-293.81M
1W Leistung:
-4.89%
1M Leistung:
-17.15%
6M Leistung:
-24.75%
1J Leistung:
+61.30%
1-Tages-Spanne:
$35.16
$36.22
1-Wochen-Bereich:
$34.88
$37.52
52-Wochen-Spanne:
$19.07
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
35.18 | 2.54B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | Eingeleitet | BofA Securities | Buy |
| 2025-08-04 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics Inc (VERA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vera Therapeutics Inc (VERA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vera Therapeutics Inc (VERA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vera Therapeutics, Inc. Revenue Breakdown – NASDAQ:VERA - TradingView
VERA|Vera Therapeutics Inc|Price:35.450|Chg%:-0.900 - TradingKey
Vera Therapeutics Inc (VERA) Institutional Confidence - TradingKey
Price to book forward of Vera Therapeutics, Inc. – NASDAQ:VERA - TradingView
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics - Stocktwits
Vera Therapeutics (VERA) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
(VERA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Vera Therapeutics stock edges higher to $37.22 as Official_VeraTx promotes SPARK 2026 event - Traders Union
Vera Therapeutics (VERA) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Price to earnings forward of Vera Therapeutics, Inc. – NASDAQ:VERA - TradingView
Vera Therapeutics Inc. (VERA) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development StageRevenue Growth Outlook - dars.gov.et
The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA’s Accelerated FDA ApprovalLearn Why - Sahm
Enterprise value to revenue forward of Vera Therapeutics, Inc. – NASDAQ:VERA - TradingView
Vera Therapeutics' Trutakna: A Dual-Mechanism Breakthrough Facing a Critical Q3 Test - Kavout | AI
Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Cuts Target Price to $43 - Moomoo
Vera Therapeutics wins FDA approval for TRUTAKNA in IgA nephropathy, sets launch - MSN
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch - TradingView
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)? - Yahoo Finance
Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced? - Sahm
Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval - Yahoo Finance
Rx Rundown: Vertex Pharmaceuticals, Real Chemistry, Vera Therapeutics and more - Medical Marketing and Media
Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
New Vera Therapeutics employees receive $40.13 stock options in inducement plan - Stock Titan
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $91 - Moomoo
Form 4 Vera Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million By Investing.com - Investing.com Nigeria
Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million - Investing.com
Vera Therapeutics (VERA) CEO preplanned sale of 46,250 shares reported - Stock Titan
Vera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade) (VERA) - Seeking Alpha
Vera Therapeutics names Nancy Boman as chief regulatory officer By Investing.com - Investing.com India
Vera Therapeutics, Inc. Files Form 8-K with SEC: Key Company and Stock Information for July 2026 - Minichart
Vera Therapeutics Announces New Chief Regulatory Officer - TipRanks
Vera Therapeutics names Nancy Boman as chief regulatory officer - Investing.com
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner - The Manila Times
Executive shakeup at Vera Therapeutics (VERA) as new Chief Regulatory Officer named - Stock Titan
Vera Therapeutics Announces Appointment of Nancy Boman as - GlobeNewswire
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $76 - Moomoo
Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval - MedCity News
Vera Therapeutics (VERA) Q4 2025 earnings summary - Quartr
Vera Therapeutics (VERA) Q1 2026 earnings summary - Quartr
Vera Therapeutics' Trutakna Pricing Tops Expectations, Wedbush Says - Moomoo
Cantor Fitzgerald reiterates Vera Therapeutics stock rating on IgAN approval By Investing.com - Investing.com South Africa
Vera Therapeutics stock price target raised to $125 by H.C. Wainwright on FDA approval By Investing.com - Investing.com South Africa
Guggenheim raises Vera Therapeutics stock price target on FDA approval By Investing.com - Investing.com India
FDA grants accelerated approval to Vera Therapeutics' Trutakna - qz.com
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):